First-In-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients With Advanced Hepatocellular Carcinoma

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-12-2616
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Phase 2 Study of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma

Journal of Gastroenterology
Gastroenterology
2016English

Recombinant Soluble Glypican 3 Protein Inhibits the Growth of Hepatocellular Carcinoma in Vitro

International Journal of Cancer
Cancer ResearchOncology
2010English

A Phase I First-In-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients With Advanced Cancer

Clinical Cancer Research
Cancer ResearchOncology
2012English

First-In-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-Her3 Monoclonal Antibody, in Patients With Metastatic or Advanced HER3-Positive Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2015English

Gemcitabine Plus Carboplatin in Patients With Advanced Hepatocellular Carcinoma: Results of a Phase II Study

ISRN Oncology
2012English

First‐in‐human Phase I Study of E7090, a Novel Selective FGFR Inhibitor, in Patients With Advanced Solid Tumors

Cancer Science
Cancer ResearchMedicineOncology
2020English

A Phase I Study of Farletuzumab, a Humanized Anti-Folate Receptor Α Monoclonal Antibody, in Patients With Solid Tumors

Investigational New Drugs
OncologyPharmacology
2014English

Phase I Study of Tomuzotuximab, a Glycoengineered Therapeutic Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Carcinomas

ESMO Open
Cancer ResearchOncology
2018English

A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients With Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake

Clinical Cancer Research
Cancer ResearchOncology
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy